adplus-dvertising
Connect with us

Health

Mounjaro, tirzepatide found effective for weight loss, Eli Lily says

Published

 on


Two trials have now found tirzepatide, sold under the brand name Mounjaro as a diabetes treatment, to be effective for weight loss. It is likely to be approved later this year.

In a second large study, the drug Mounjaro, now used to treat diabetes, has shown its effectiveness at helping people lose weight.

The drug is not yet approved for weight loss, but likely will be later this year, now that two trials have found it effective with similar side effects as other weight loss medications.

The study, released by drug-maker Eli Lilly on Thursday, showed participants with diabetes lost nearly 16% of their weight over the 18-month trial. The company had already shown that the same drug, generically called tirzepatide, could help people with obesity but not diabetes lose more than 20% of their body weight.

It is generally harder for people with diabetes to lose weight and this is the first drug trial to show such significant weight loss for people with the disease, according to Lilly associate vice president Dr. Nadia Nazir Ahmad.

So far, data on the drug has only been released via a company press release. Ahmad said Lilly plans to release full results at the American Diabetes Association’s annual meeting in San Diego in June and submit them to a peer-reviewed journal.

 

What is tirzepatide and how does it compare to Ozempic and Wegovy?

Tirzepatide, sold under the brand name Mounjaro, is approved for the treatment of diabetes.

It is believed to act on obesity in two ways, Ahmad said, by reducing appetite and affecting how the body burns fat.

Semaglutide, the generic name for the drug in both Ozempic and Wegovy, acts only on the first of those and thus appears to be slightly less effective at promoting weight loss, though they have never been compared in a head-to-head study. Lilly is currently in the planning stages for one, Ahmad said

Both semaglutide and tirzepatide are delivered by weekly injection.

Ozempic, Wegovy, Mounjaro: How these medications promote weight loss

What did the new trial show?

The new trial included 938 adults, one-third of whom received a 10-mg dose of tirzepatide, one-third received a 15-mg dose, and one-third a placebo.

Those on the lower dose lost about 13% of their body weight, or about 30 pounds. That compares to nearly 16% weight loss of those on the higher dose, or about 34 pounds, and 3% or 7 pounds among those getting the placebo.

Less than 3% of the placebo group lost more than 15% of their body weight, compared to 40% of the low-dose group and 48% of the high-dose group.

A measure of diabetes severity, A1C also fell in people taking the drug.

Lilly has not said what dose it will request for approval from the Food and Drug Administration for weight loss.

Mounjaro is meant to be ramped up from a low, introductory dose of 2.5 mg to as much as 15 mg per weekly dose. The highest dose costs about $1,000 per month. Wegovy, which is a higher dose of the same drug as Ozempic, retails for about $1,300 a month.

Insurance, including the government’s Medicare and Medicaid, typically covers the cost of medications for diabetes but not for weight loss.

 

What happens if you stop taking Mounjaro?

These weight-loss medications are intended to be taken monthly for life.

Lilly’s Ahmad noted that no one would think they could stop taking their blood pressure medication once their numbers reached a healthy level.

More: Obesity was long considered a personal failing. Science shows it’s not.

Studies have shown that people tend to regain at least some of the weight once stopping medication. In the new trial, called SURMOUNT-2, Lilly followed patients for four weeks after stopping tirzepatide and found they began to regain.

The company is running another randomized study to look at what happens longer term after people stop the drug.

Side effects of Mounjaro

Tirzepatide and semaglutide have similar side effects. In the new trial, about 20% of people at both drug doses suffered nausea and diarrhea, 12% endured vomiting and 8% had constipation. In the placebo group, 6% had nausea, 9% diarrhea, 3% vomiting and 4% constipation.

Nearly 4% of those receiving placebo dropped out of the trial because of side effects, compared to the same percentage of people on the lower dose and 7% on the higher dose. Overall, a higher percentage of people receiving the placebo dropped out of the trial than those receiving the drug.

Lifestyle changes and tirzepatide

Lifestyle changes remain important while on tirzepatide, Ahmad said, but differ slightly from the typical recommendations.

When appetite is suppressed and the body is losing weight, she said, it’s particularly important to eat a healthy diet and stay hydrated.

“Lifestyle is important with medications that treat chronic diseases,” she said.

Contact Karen Weintraub at kweintraub@usatoday.com.

Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.

 

728x90x4

Source link

Continue Reading

Health

Whooping cough is at a decade-high level in US

Published

 on

 

MILWAUKEE (AP) — Whooping cough is at its highest level in a decade for this time of year, U.S. health officials reported Thursday.

There have been 18,506 cases of whooping cough reported so far, the Centers for Disease Control and Prevention said. That’s the most at this point in the year since 2014, when cases topped 21,800.

The increase is not unexpected — whooping cough peaks every three to five years, health experts said. And the numbers indicate a return to levels before the coronavirus pandemic, when whooping cough and other contagious illnesses plummeted.

Still, the tally has some state health officials concerned, including those in Wisconsin, where there have been about 1,000 cases so far this year, compared to a total of 51 last year.

Nationwide, CDC has reported that kindergarten vaccination rates dipped last year and vaccine exemptions are at an all-time high. Thursday, it released state figures, showing that about 86% of kindergartners in Wisconsin got the whooping cough vaccine, compared to more than 92% nationally.

Whooping cough, also called pertussis, usually starts out like a cold, with a runny nose and other common symptoms, before turning into a prolonged cough. It is treated with antibiotics. Whooping cough used to be very common until a vaccine was introduced in the 1950s, which is now part of routine childhood vaccinations. It is in a shot along with tetanus and diphtheria vaccines. The combo shot is recommended for adults every 10 years.

“They used to call it the 100-day cough because it literally lasts for 100 days,” said Joyce Knestrick, a family nurse practitioner in Wheeling, West Virginia.

Whooping cough is usually seen mostly in infants and young children, who can develop serious complications. That’s why the vaccine is recommended during pregnancy, to pass along protection to the newborn, and for those who spend a lot of time with infants.

But public health workers say outbreaks this year are hitting older kids and teens. In Pennsylvania, most outbreaks have been in middle school, high school and college settings, an official said. Nearly all the cases in Douglas County, Nebraska, are schoolkids and teens, said Justin Frederick, deputy director of the health department.

That includes his own teenage daughter.

“It’s a horrible disease. She still wakes up — after being treated with her antibiotics — in a panic because she’s coughing so much she can’t breathe,” he said.

It’s important to get tested and treated with antibiotics early, said Dr. Kris Bryant, who specializes in pediatric infectious diseases at Norton Children’s in Louisville, Kentucky. People exposed to the bacteria can also take antibiotics to stop the spread.

“Pertussis is worth preventing,” Bryant said. “The good news is that we have safe and effective vaccines.”

___

AP data journalist Kasturi Pananjady contributed to this report.

___

The Associated Press Health and Science Department receives support from the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Scientists show how sperm and egg come together like a key in a lock

Published

 on

 

How a sperm and egg fuse together has long been a mystery.

New research by scientists in Austria provides tantalizing clues, showing fertilization works like a lock and key across the animal kingdom, from fish to people.

“We discovered this mechanism that’s really fundamental across all vertebrates as far as we can tell,” said co-author Andrea Pauli at the Research Institute of Molecular Pathology in Vienna.

The team found that three proteins on the sperm join to form a sort of key that unlocks the egg, allowing the sperm to attach. Their findings, drawn from studies in zebrafish, mice, and human cells, show how this process has persisted over millions of years of evolution. Results were published Thursday in the journal Cell.

Scientists had previously known about two proteins, one on the surface of the sperm and another on the egg’s membrane. Working with international collaborators, Pauli’s lab used Google DeepMind’s artificial intelligence tool AlphaFold — whose developers were awarded a Nobel Prize earlier this month — to help them identify a new protein that allows the first molecular connection between sperm and egg. They also demonstrated how it functions in living things.

It wasn’t previously known how the proteins “worked together as a team in order to allow sperm and egg to recognize each other,” Pauli said.

Scientists still don’t know how the sperm actually gets inside the egg after it attaches and hope to delve into that next.

Eventually, Pauli said, such work could help other scientists understand infertility better or develop new birth control methods.

The work provides targets for the development of male contraceptives in particular, said David Greenstein, a genetics and cell biology expert at the University of Minnesota who was not involved in the study.

The latest study “also underscores the importance of this year’s Nobel Prize in chemistry,” he said in an email.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Turn Your Wife Into Your Personal Sex Kitten

Published

 on

Product Name: Turn Your Wife Into Your Personal Sex Kitten

All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.

Turn Your Wife Into Your Personal Sex Kitten is backed with a 60 Day No Questions Asked Money Back Guarantee. If within the first 60 days of receipt you are not satisfied with Wake Up Lean™, you can request a refund by sending an email to the address given inside the product and we will immediately refund your entire purchase price, with no questions asked.

(more…)

Continue Reading

Trending